A heart attack treatment of an Indian firm has to look for a part of the arteries and stem cell treatment, its kind in the country, local newspaper Today's first match for the clinical trial is started Tuesday.
The treatment, launched by Bangalore - based research firm Stempeutics, adult bone marrow cells from patients so that they move the heart and muscles heal, it better help develop green needle, including the report said.
Cells through an injection on a demand from doctors through the Hotline can be administered. Stem cells, unprogrammed cells that could grow in a variety of tissues, this is premature, according to a report.
The report cells for distributors in India and abroad will be supplied.
Similar tests, a U.S. biotech company Osiris therapy two major products, a Crohn's disease and is associated with a bone marrow transplant and associated with.
Prochymal test last month, the company, which experienced the first time heart attack patients continue to have a heart for damages for the evaluation of treatment results be published. In addition, an Australian company with two similar products is expected to come.
Indian products, for the large-scale testing are complete, the product to hit shelves until 2011, according to the report is expected.
"We already will soon start two pilot studies and clinical trials have," the newspaper quoted Stempeutics BN Manohar, president as saying.
Indian Medical Research Council and the Drug Controller General of India with the company already has approved the protocol
No comments:
Post a Comment